Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-02
2006-05-02
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S019300, C530S330000, C530S331000, C530S345000
Reexamination Certificate
active
07037898
ABSTRACT:
The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.
REFERENCES:
patent: 4277466 (1981-07-01), Trouet et al.
patent: 4296105 (1981-10-01), Baurain et al.
patent: 4376765 (1983-03-01), Trouet et al.
patent: 4388305 (1983-06-01), Trouet et al.
patent: 4639456 (1987-01-01), Trouet et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 4719312 (1988-01-01), Firestone
patent: 4870162 (1989-09-01), Trouet et al.
patent: 5024835 (1991-06-01), Rao et al.
patent: 5220001 (1993-06-01), Ok et al.
patent: 5599686 (1997-02-01), DeFeo-Jones et al.
patent: 5618790 (1997-04-01), Kennedy et al.
patent: 5962216 (1999-10-01), Trouet et al.
patent: 6143864 (2000-11-01), DeFeo-Jones et al.
patent: 6342480 (2002-01-01), Trouet et al.
patent: 869 485 (1978-12-01), None
patent: 882 541 (1980-07-01), None
patent: 0 041 935 (1981-12-01), None
patent: 0 044 090 (1982-01-01), None
patent: 0 126 685 (1984-11-01), None
patent: 0 208 615 (1987-01-01), None
patent: 0 208 615 (1987-01-01), None
patent: 0 126 344 (1994-11-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 93/02703 (1993-02-01), None
patent: WO 96/00503 (1996-01-01), None
patent: WO 96/33198 (1996-10-01), None
patent: WO 00/69472 (2000-11-01), None
patent: WO 01/28593 (2001-04-01), None
patent: WO 01/30804 (2001-05-01), None
Balajthy et al., “Synthesis and Functional Evaluation of a Peptide Derivative of 1-β-D-Arabinofuranosylcytosine,”. J. Med. Chem., vol. 35, pp. 3344-3349, 1992.
Baurain et al., “Antitumor Activity of Daunorubicin Linked to Proteins: Lysosomal Hydrolysis and Antitumor Activity of Conjugates Prepared With Peptidic Spacer Arms,” Chem. Abstr., #97: 150636, 1982.
Baurain et al., “Amino Acid and Dipeptide Derivatives of Daonorubicin. 2. Cellular Pharmacology and Antitumor Activity on L1210 Leukemic Cells in Vitro and in Vivo,” J. Med. Chem, vol. 23, pp. 1171-1174, 1980.
Chakravarty et al., “Plasmin-Activated Prodrugs for Cancer Chemotherapy. 1. Synthesis and Biological Activity of Peptidylacivicin and Peptidylphenylenediamine,” J. Med. Chem., vol. 26: 633-638, 1983.
Chakravarty et al., “Plasmin-Activated Prodrugs for Cancer Chemotherapy. 2. Synthesis and Biological Activity of Peptidyl Derivatives of Doxorubicin,” J. Med. Chem., vol. 26: 638-644, 1983.
De Marre et al., “Evaluation of the Hydrolytic and Enzymatic Stability of Macromolecular Mitomycin C Derivatives,” J. Controlled Release, vol. 31, pp. 89-97, 1994.
Eisenbrand et al., “An Approach Towards More Selective Anticancer Agents,” Synthesis, pp. 1246-1258, Oct. 1996.
Kennett et al., “Comparative Histochemical, Biochemical and Immunocytochemical Studies of Cathepsin B in Human Gingiva,” Chem. Abstr., #121: 79924, 1994.
Masquelier et al., “Amino Acid and Dipeptide Derivatives of Daunorubicin. 1. Synthesis, Physicochemical Properties, and Lysosomal Digestion,” J. Med. Chem., vol. 23, pp. 1166-1170, 1980.
Masquelier et al., “Antitumor Activity of Daunorubicin Linked to Proteins: Biological and Antitumor Properties of Peptidic Derivatives of Daunorubicin Used as Interediates,” Chem. Abstr., #97: 150635, 1982.
Seitz et al., “Synthesis and Chemical Properties of a Series of Doxorubicin Enaminomalonyl-, β—Alanine Derivatives,” Tetrahedron Lett., vol. 3, No. 9, pp. 1413-1416, 1995.
Whalley, “Receptors Mediating the Increase in Vascular Permeability to Kinins: Comparative Studies in Rat, Guinea Pig and Rabbit,” Chem. Abstr., #107: 127965, 1987.
Baurain, et al., “Targeting of Daunorubicin by Covalent and Reversible Linkage to Carrier Proteins. Lysosomal Hydrolysis and Antitumoral Activity of Conjugates Prepared with Peptidic Spacers.”Drugs Exp. Clin., vol. 9, pp 303-311, 1983.
Harnois-Pontoni, I. et al., “Hydrosoluble Fluorogenic Substrates for Plasmin” Analytical Biochemistry, 193, 248-255 (1991).
Hoes and Feijen “The Application of Drug-Polymer Conjugates in Chemotherapy” in Horizons in Biochemistry and Biophysics vol. 9: Drug Carrier Systems, pp. 57-109 (1989).
Israel, M. et al., “Adriamycin Analogues. Preparation and Biological Evaluation of Some N-(Trifluoroacetyl)-14-O-[(N-acetylamino) acyl] adriamycin Derivatives” J. of Med. Chem., 1986, vol. 29, 1273-1276.
Kandukuri, S. P., et al., “Vinblastin-23-oyl Amino Acid Derivatives: Chemistry, Physicochemical Data, Toxicity and Antitumor Activities against P388 and L1210 Leukemias” Journal of Medicinal Chemistry, 1985, vol. 28, No. 8, 1079-1088.
Masquelier, et al., “Antitumor Activity of Daunorubicin Linked to Proteins: Biological and Antitumor Properties of Peptidic Derivatives of Daunorubicin Used as Intermediates,” Curr. Chemo. and Immunotherapy, Proc. of the 12thIntl. Congress of Chemotherapy (1982), vol. 2, pp 1428-32.
Mayer, R., et al., “Peptide Derivatives Specific for aPlasmodium falciparumProteinase Inhibit the Human Erythrocyte Invasion by Merozoites” Journal of Medicinal Chemistry, 1991, vol. 34, 3029-3038.
Pozsgay, M. et al., “A Method for Designing Peptide Substrates for Proteases: Tripeptidal-p-nitroanilide Substrates for Subtilisin Carlsberg” European Journal of Biochemistry vol. 95: 115-119 (1979).
Said, et al., “Systemic Treatment: Methotrexate” Clinics in Dermatology 15:781-797 (1997).
Taylor & Amidon (eds.) Peptide-Based Drug Design, Controlling Transport and Metabolism, 1995, 423-445, 449-467 (2 chapters).
Trail, P.A., et al., “Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates” Science vol. 261, Jul. 9, 1993, 212-215.
Trouet, et al. “A Covalent Linkage between Daunorubicin and Proteins That Is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for a Lysosomotropic Drug-Carrier Conjugate: In Vitro and In Vivo Studies” Proc. Natl. Acad. Sci. USA 79:626-629 (1982).
Tugwell, et al., “Methotrexate in Rheumatoid Arthritis” Ann. Internal Med. 107:358-366 (1987).
Opposition to AU 694546, Notice of Opposition, dated Oct. 23, 1998.
Opposition to AU 694546, Statement of Grounds and Particulars on behalf of Opponent Merck & Co., Inc., dated Jan. 25, 1999.
Opposition to AU 694546, Declaration of Andrew Lee on behalf of Opponent Merck & Co., Inc., executed Jul. 15, 1999 (including Exhibits D1 to D33).
Opposition to AU 694546, Declaration of Veronika Judit Bender on behalf of Opponent Merck & Co., Inc., executed Mar. 14, 2000 (including Exhibits VJB-1, VJB-3 to VJB-10).
Opposition to AU 694546, Declaration of Geoffrey William Tregear on behalf of Opponent Merck & Co., Inc., executed on Apr. 26, 2000 (including Exhibit GWT-1).
Opposition to AU 694546, Declaration of David Courtland Heimbrook on behalf of Opponent Merck & Co., Inc., executed Apr. 20, 2000 (including Exhibit DCH-1).
Opposition to AU 694546, Letter to The Commissioner of Patents, IP Australia, from Geoff Davidson, Halford & Co., enclosing Evidence in Answer on behalf of Applicants La Region Wallone and Université Catholique De Louvain, dated Aug. 27, 2001.
Opposition to AU 694546, Statutory Declaration of Geoffrey Allan Pietersz on behalf of Applicants La Region Wallone an
Baurain Roger
Trouet Andre
Huff Sheela J.
LaRegion Wallone
Remillard, Esq. James E.
Soroos, Esq. Cynthia M.
Universite Catholique de Louvain
LandOfFree
Tumor-activated prodrug compounds and treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor-activated prodrug compounds and treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor-activated prodrug compounds and treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3579519